Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

[Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients].

Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG.

Med Clin (Barc). 2005 Sep 10;125(8):281-5. Spanish.

PMID:
16159550
2.

Thiopurine methyltransferase activity in Spain: a study of 14,545 patients.

Gisbert JP, Gomollón F, Cara C, Luna M, González-Lama Y, Pajares JM, Maté J, Guijarro LG.

Dig Dis Sci. 2007 May;52(5):1262-9. Epub 2007 Mar 2.

PMID:
17334911
3.

[Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine].

Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.

Med Clin (Barc). 2003 Jun 7;121(1):1-5. Spanish.

PMID:
12812701
4.

Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.

Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG.

Am J Gastroenterol. 2006 Dec;101(12):2769-76. Epub 2006 Oct 6.

PMID:
17026564
5.

Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?

Fangbin Z, Xiang G, Minhu C, Liang D, Feng X, Min H, Pinjin H.

Ther Drug Monit. 2012 Dec;34(6):695-701. doi: 10.1097/FTD.0b013e3182731925.

PMID:
23149442
6.

Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.

Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM.

Clin Gastroenterol Hepatol. 2004 May;2(5):410-7.

PMID:
15118980
8.

Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M.

Clin Pharmacokinet. 2007;46(3):187-208. Review.

PMID:
17328579
9.

Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.

Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.

Hepatogastroenterology. 2006 May-Jun;53(69):399-404.

PMID:
16795981
10.

Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.

González-Lama Y, Bermejo F, López-Sanromán A, García-Sánchez V, Esteve M, Cabriada JL, McNicholl AG, Pajares R, Casellas F, Merino O, Carpio D, Vera MI, Muñoz C, Calvo M, Benito LM, Bujanda L, García-Fernández FJ, Ricart E, Ginard D, Velasco M, Carneros JA, Manceñido N, Calvo M, Algaba A, Froilan C, Cara C, Maté J, Abreu L, Gisbert JP; "Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)".

Aliment Pharmacol Ther. 2011 Sep;34(5):544-54. doi: 10.1111/j.1365-2036.2011.04756.x. Epub 2011 Jul 3.

11.
12.

Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.

Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN.

J Clin Gastroenterol. 2000 Jun;30(4):409-13.

PMID:
10875470
13.

Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.

Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, Meenan J, Yim A, Sanderson J.

Aliment Pharmacol Ther. 2002 Oct;16(10):1743-50.

14.

5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.

Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S.

Inflamm Bowel Dis. 2006 Apr;12(4):251-7.

PMID:
16633046
15.

Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.

Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML.

Clin Gastroenterol Hepatol. 2008 Jun;6(6):654-60; quiz 604. doi: 10.1016/j.cgh.2008.02.032. Epub 2008 May 7.

PMID:
18467186
16.

[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].

Alvarez Beltran M, Infante Pina D, Tormo Carnicé R, Segarra Cantón O, Redecillas Ferreiro S.

An Pediatr (Barc). 2009 Feb;70(2):126-31. doi: 10.1016/j.anpedi.2008.10.010. Epub 2009 Feb 3. Spanish.

17.

The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.

Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.

J Crohns Colitis. 2014 Feb;8(2):120-8. doi: 10.1016/j.crohns.2013.07.004. Epub 2013 Aug 7.

PMID:
23932783
18.

Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.

Cao Q, Zhu Q, Shang Y, Gao M, Si J.

Digestion. 2009;79(1):58-63. doi: 10.1159/000205268. Epub 2009 Feb 28.

PMID:
19252404
19.

Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.

Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA.

Aliment Pharmacol Ther. 2003 Aug 15;18(4):395-400.

20.

Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.

Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.

Intern Med J. 2005 Oct;35(10):580-5.

PMID:
16207256

Supplemental Content

Support Center